In its most significant deal to date, Protherics plc licensed rights to its late-stage sepsis drug candidate to AstraZeneca plc for a potential £195 million (US$341 million). (BioWorld Today)

In its most significant deal to date, Protherics plc licensed rights to its late-stage sepsis drug candidate to AstraZeneca plc for a potential £195 million (US$341 million). (BioWorld Today)

ViroPharma Inc. is raising $150.7 million through a public offering to support business development activities and general corporate purposes, as well as to pay off a portion of the company's debt. (BioWorld Today)

ViroPharma Inc. is raising $150.7 million through a public offering to support business development activities and general corporate purposes, as well as to pay off a portion of the company's debt. (BioWorld Today)